Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer

[1]  Angela Patricia Beltrán-López.  Asociación de variantes genéticas en el gen DEAR1 con cáncer de seno y desenlace clínico en población colombiana , 2020 .

[2]  H. Ditzel,et al.  Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer , 2018, Molecular oncology.

[3]  L. Pusztai,et al.  Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. , 2017 .

[4]  H. Pan,et al.  Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis , 2017, Oncotarget.

[5]  Aiko Sueta,et al.  Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients , 2017, Translational oncology.

[6]  Xuelei Ma,et al.  Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis , 2017, Oncotarget.

[7]  R. Hastings,et al.  Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. , 2017, Clinical chemistry.

[8]  S. Noguchi,et al.  Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing. , 2016, Clinical breast cancer.

[9]  C. Harris,et al.  Clinical Outcomes of TP53 Mutations in Cancers. , 2016, Cold Spring Harbor perspectives in medicine.

[10]  Q. Sun,et al.  Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy , 2016, PloS one.

[11]  K. Wiman,et al.  Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer , 2016, Journal of Ovarian Research.

[12]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[13]  L. Abrahmsén,et al.  Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy , 2016, Front. Oncol..

[14]  J. Picquenot,et al.  Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer , 2015, International journal of cancer.

[15]  M. Dowsett,et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.

[16]  Adrian V. Lee,et al.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients , 2015, Clinical Cancer Research.

[17]  Tetsuya Nakamura,et al.  Biological markers of invasive breast cancer. , 2015, Japanese journal of clinical oncology.

[18]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[19]  P. Stephens,et al.  Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations , 2015, Breast Cancer Research and Treatment.

[20]  A. Marchetti,et al.  Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  N. Tunariu,et al.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.

[22]  Olivier Lantz,et al.  Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients , 2015, International journal of cancer.

[23]  J. García-Saenz,et al.  Abstract P4-02-10: Detection of H1047R and E545K PIK3CA mutations from peripheral blood in ER positive breast cancer patients , 2015 .

[24]  Haifeng Xu,et al.  Value of Quantitative and Qualitative Analyses of Circulating Cell-Free DNA as Diagnostic Tools for Hepatocellular Carcinoma , 2015, Medicine.

[25]  T. Mok,et al.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.

[26]  S. Noguchi,et al.  PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients , 2015, Breast Cancer Research and Treatment.

[27]  P. Angenendt,et al.  Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies , 2015, Oncotarget.

[28]  S Michiels,et al.  Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  T. Takano.  JS4-5INDIVIDUALIZED TREATMENT FOR HER2-POSITIVE BREAST CANCER , 2014 .

[30]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Stephens,et al.  A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.

[33]  Antonio C. Wolff,et al.  Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer , 2014, Clinical Cancer Research.

[34]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[35]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[36]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[37]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[38]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[39]  Rosette Lidereau,et al.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.

[40]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[41]  P. Angenendt,et al.  Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC). , 2011, Journal of Clinical Oncology.

[42]  J. Shaw,et al.  Detection of HER2 amplification in circulating free DNA in patients with breast cancer , 2011, British Journal of Cancer.

[43]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[44]  M. Ranson,et al.  Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer , 2010, Breast Cancer Research and Treatment.

[45]  Patrick Bossuyt,et al.  Systematic Reviews of Diagnostic Test Accuracy , 2008, Annals of Internal Medicine.

[46]  Jonathan J Deeks,et al.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. , 2005, Journal of clinical epidemiology.

[47]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[48]  P. Bossuyt,et al.  The diagnostic odds ratio: a single indicator of test performance. , 2003, Journal of clinical epidemiology.

[49]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, Annals of Internal Medicine.

[50]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[51]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[52]  C. Harris,et al.  Clinical Outcomes of TP 53 Mutations in Cancers , 2016 .

[53]  Jenny C. Chang,et al.  Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients , 2015, Breast Cancer Research and Treatment.

[54]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[55]  L. V. van't Veer,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). , 2014, Breast.